Oligonucleotide therapeutics in neurodegenerative diseases

References

• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259–293.
   PubMed Web of Science ®Google Scholar
• Dallas A, Vlassov AV. RNAi: a novel antisense technology and its therapeutic potential. Med Sci Monit. 2006;12(4):RA67–74.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med. 2004;351(27):2805–2816.
   PubMed Web of Science ®Google Scholar
• Lebruska LL, Maher LJ, 3rd. Selection and characterization of an RNA decoy for transcription factor NF-kappa B. Biochemistry. 1999;38(10):3168–3174.
   PubMed Web of Science ®Google Scholar
• Boudreau RL, Davidson BL. Generation of hairpin-based RNAi vectors for biological and therapeutic application. Methods Enzymol. 2012;507:275–296.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555.
   PubMed Web of Science ®Google Scholar
• Tahara K, Hashimoto W, Takeuchi H. Inhalation properties and stability of nebulized naked siRNA solution for pulmonary therapy. Chem Pharm Bull (Tokyo). 2016;64(1):63–67.
   PubMed Web of Science ®Google Scholar
• Keiser MS, Boudreau RL, Davidson BL. Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy. Mol Ther. 2014;22(3):588–595.
   PubMed Web of Science ®Google Scholar
• Hocquemiller M, Giersch L, Audrain M, et al. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27(7):478–496.
   PubMed Web of Science ®Google Scholar
• Ramachandran PS, Keiser MS, Davidson BL. Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics. 2013;10(3):473–485.
   PubMed Web of Science ®Google Scholar
• Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther. 2013;20(4):450–459.
   PubMed Web of Science ®Google Scholar
• Deyle DR, Russell DW. Adeno-associated virus vector integration. Curr Opin Mol Ther. 2009;11(4):442–447.
   PubMedGoogle Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811.
   PubMed Web of Science ®Google Scholar
• Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res. 2011;717(1-2):1–8.
   PubMed Web of Science ®Google Scholar
• Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–669.
   PubMed Web of Science ®Google Scholar
• Gao WY, Han FS, Storm C, et al. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol. 1992;41(2):223–229.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Lemonidis KM, Neilson L, et al. Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes. The Biochemical journal. 1995;312(Pt 2):599–608.
   PubMed Web of Science ®Google Scholar
• Marwick C. First “antisense” drug will treat CMV retinitis. JAMA. 1998;280(10):871.
   PubMed Web of Science ®Google Scholar
• Crooke ST. Vitravene–another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 1998;8(4):vii–viii.
   PubMedGoogle Scholar
• Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19(1):60–71.
   PubMed Web of Science ®Google Scholar
• Sune-Pou M, Prieto-Sanchez S, Boyero-Corral S, et al. Targeting splicing in the treatment of human disease. Genes (Basel). 2017;8(3):E87.
   PubMed Web of Science ®Google Scholar
• Keeling KM, Xue X, Gunn G, et al. Therapeutics based on stop codon readthrough. Annu Rev Genomics Hum Genet. 2014;15:371–394.
   PubMed Web of Science ®Google Scholar
• Adams BD, Parsons C, Walker L, et al. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127(3):761–771.
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178.
   PubMed Web of Science ®Google Scholar
• Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452(7187):591–597.
   PubMed Web of Science ®Google Scholar
• Deng Y, Chen J, Zhao Y, et al. Transdermal delivery of siRNA through Microneedle Array. Sci Rep. 2016;6:21422.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Wang S, Vickers TA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017;35(3):230–237.
   PubMed Web of Science ®Google Scholar
• Geary RS, Norris D, Yu R, et al. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46–51.
   PubMed Web of Science ®Google Scholar
• Detzer A, Overhoff M, Mescalchin A, et al. Phosphorothioate-stimulated cellular uptake of siRNA: a cell culture model for mechanistic studies. Curr Pharm Des. 2008;14(34):3666–3673.
   PubMed Web of Science ®Google Scholar
• Prakash S, Malhotra M, Rengaswamy V. Nonviral siRNA delivery for gene silencing in neurodegenerative diseases. Methods Mol Biol. 2010;623:211–229.
   PubMedGoogle Scholar
• Niu S, Zhang LK, Zhang L, et al. Inhibition by multifunctional magnetic nanoparticles loaded with Alpha-synuclein RNAi plasmid in a Parkinson's disease model. Theranostics. 2017;7(2):344–356.
   PubMed Web of Science ®Google Scholar
• Shyam R, Ren Y, Lee J, et al. Intraventricular delivery of siRNA nanoparticles to the central nervous system. Mol Ther Nucleic Acids. 2015;4:e242.
   PubMedGoogle Scholar
• Malhotra M, Tomaro-Duchesneau C, Saha S, et al. Intranasal delivery of chitosan-siRNA nanoparticle formulation to the brain. Methods Mol Biol. 2014;1141:233–247.
   PubMedGoogle Scholar
• Rietwyk S, Peer D. Next-generation lipids in RNA interference therapeutics. ACS Nano. 2017;11(8):7572–7586.
   PubMed Web of Science ®Google Scholar
• Godfrey C, Desviat LR, Smedsrod B, et al. Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med. 2017;9(5):545–557.
   PubMed Web of Science ®Google Scholar
• Medina-Kauwe LK. Development of adenovirus capsid proteins for targeted therapeutic delivery. Ther Deliv. 2013;4(2):267–277.
   PubMedGoogle Scholar
• Medina-Kauwe LK, Maguire M, Kasahara N, et al. Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Gene Ther. 2001;8(23):1753–1761.
   PubMed Web of Science ®Google Scholar
• DeVos SL, Miller TM. Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics. 2013;10(3):486–497.
   PubMed Web of Science ®Google Scholar
• Ward AJ, Norrbom M, Chun S, et al. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides. Nucleic Acids Res. 2014;42(9):5871–5879.
   PubMed Web of Science ®Google Scholar
• Carroll JB, Warby SC, Southwell AL, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178–2185.
   PubMed Web of Science ®Google Scholar
• Southwell AL, Skotte NH, Bennett CF, et al. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med. 2012;18(11):634–643.
   PubMed Web of Science ®Google Scholar
• Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuroendocrinology. 2012;74(6):1031–1044.
   Google Scholar
• Scoles DR, Meera P, Schneider MD, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017;544:362–366.
   PubMed Web of Science ®Google Scholar
• Duyao MP, Auerbach AB, Ryan A, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 1995;269(5222):407–410.
   PubMed Web of Science ®Google Scholar
• Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81(5):811–823.
   PubMed Web of Science ®Google Scholar
• Zeitlin S, Liu JP, Chapman DL, et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet. 1995;11(2):155–163.
   PubMed Web of Science ®Google Scholar
• Kiehl TR, Nechiporuk A, Figueroa KP, et al. Generation and characterization of Sca2 (ataxin-2) knockout mice. Biochem Biophys Res Commun. 2006;339(1):17–24.
   PubMed Web of Science ®Google Scholar
• Huynh DP, Maalouf M, Silva AJ, et al. Dissociated fear and spatial learning in mice with deficiency of ataxin-2. PLoS One. 2009;4(7):e6235.
   PubMed Web of Science ®Google Scholar
• Moore LR, Rajpal G, Dillingham IT, et al. Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models. Mol Ther Nucleic Acids. 2017;7:200–210.
   PubMedGoogle Scholar
• Gagnon KT, Pendergraff HM, Deleavey GF, et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry. 2010;49(47):10166–10178.
   PubMed Web of Science ®Google Scholar
• Hu J, Matsui M, Gagnon KT, et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol. 2009;27(5):478–484.
   PubMed Web of Science ®Google Scholar
• Rigo F, Seth PP, Bennett CF. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects. Adv Exp Med Biol. 2014;825:303–352.
   PubMed Web of Science ®Google Scholar
• Rigo F, Chun SJ, Norris DA, et al. Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J Pharmacol Exp Ther. 2014;350(1):46–55.
   PubMed Web of Science ®Google Scholar
• Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 2010;24(15):1634–1644.
   PubMed Web of Science ®Google Scholar
• Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890–897.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–3026.
   PubMed Web of Science ®Google Scholar
• Aartsma-Rus A. FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides. Nucleic Acid Ther. 2017;27(2):67–69.
   PubMed Web of Science ®Google Scholar
• Rotunno MS, Bosco DA. An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. Front Cell Neurosci. 2013;7:253.
   PubMed Web of Science ®Google Scholar
• Winer L, Srinivasan D, Chun S, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 2013;70(2):201–207.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435–442.
   PubMed Web of Science ®Google Scholar
• Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuroendocrinology. 2017;94(6):1056–1070.
   Google Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuroendocrinology. 2011;72(2):245–256.
   Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuroendocrinology. 2011;72(2):257–268.
   Google Scholar
• Taylor JP, Brown RH, Jr., Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197–206.
   PubMed Web of Science ®Google Scholar
• Mori K, Arzberger T, Grasser FA, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 2013;126(6):881–893.
   PubMed Web of Science ®Google Scholar
• Zu T, Liu Y, Banez-Coronel M, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 2013;110(51):E4968–4977.
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuroendocrinology. 2013;80(2):415–428.
   Google Scholar
• Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110(47):E4530–4539.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zhu Q, Gendron TF, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuroendocrinology. 2016;90(3):535–550.
   Google Scholar
• DeVos SL, Goncharoff DK, Chen G, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci. 2013;33(31):12887–12897.
   PubMed Web of Science ®Google Scholar
• DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481.
   PubMed Web of Science ®Google Scholar
• Hinrich AJ, Jodelka FM, Chang JL, et al. Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides. EMBO Mol Med. 2016;8(4):328–345.
   PubMed Web of Science ®Google Scholar
• Dansithong W, Paul S, Figueroa KP, et al. Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet. 2015;11(4):e1005182.
   PubMed Web of Science ®Google Scholar
• Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069–1075.
   PubMed Web of Science ®Google Scholar
• Becker LA, Huang B, Bieri G, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367–371.
   PubMed Web of Science ®Google Scholar
• Nelson SF, Crosbie RH, Miceli MC, et al. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol. 2009;22(5):532–538.
   PubMed Web of Science ®Google Scholar
• Lim KR, Maruyama R, Yokota T. Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther. 2017;11:533–545.
   PubMed Web of Science ®Google Scholar